Estrogen receptors (ERs) are critical regulators of breast cancer development. Identification of molecules that regulate the function of ERs may facilitate the development of more effective breast cancer treatment strategies. In this study, we showed that the forkhead transcription factor FOXK2 interacted with ERa, and inhibited ERa-regulated transcriptional activities by enhancing the ubiquitin-mediated degradation of ERa. This process involved the interaction between FOXK2 and BRCA1/BARD1, the E3 ubiquitin ligase of ERa. FOXK2 interacted with BARD1 and acted as a scaffold protein for BRCA1/BARD1 and ERa, leading to enhanced degradation of ERa, which eventually accounted for its decreased transcriptional activity. Consistent with these observations, overexpression of FOXK2 inhibited the transcriptional activity of ERa, decreased the transcription of ERa target genes, and suppressed the proliferation of ERa-positive breast cancer cells. In contract, knockdown of FOXK2 in MCF-7 cells promoted cell proliferation. However, when ERa was also knocked down, knockdown of FOXK2 had no effect on cell proliferation. These findings suggested that FOXK2 might act as a negative regulator of ERa, and its association with both ERa and BRCA1/BARD1 could lead to the down-regulation of ERa transcriptional activity, effectively regulating the function of ERa.
enzyme (E2), and ubiquitin ligases (E3). Among the three enzymes, only E3 ubiquitin ligases physically interact with their substrates, and therefore confer some degree of specificity. Several E3 ubiquitin ligases are known to associate with the ubiquitination of ERa, include the C terminus of Hsc70-interacting protein (CHIP), Breast cancer type 1 susceptibility protein (BRCA1)/BRCA1-associated RING domain protein 1 (BARD1), murine double minute 2 (MDM2) and ring finger protein (RNF31) [13] [14] [15] [16] . Among them, BRCA1/ BARD1 complex is a well-known E3 ubiquitin ligase, and it has been widely investigated. BRCA1/BARD1 plays important roles in DNAdamage response and tumor suppression through degrading a set of substrates such as RNA pol II and FANCD2 in addition to ERa 17 .
Forkhead box K2 (FOXK2), also known as ILF or ILF1, is one of the forkhead transcription factors that contain a conserved forkhead winged helix-turn-helix DNA binding domain (FOX domain). It was first identified as a regulator of IL-2 transcription, where it acts as a transcriptional repressor 18 . In common with other forkhead transcription factors, FOXK2 contains a FOX domain in addition to a FHA domain that mediates its interaction with other proteins. The function of FOXK2 is regulated by the CDK1/Cyclin B kinase complex which modulates its stability and activity 19 . FOXK2 interacts with AP-1, and promotes the binding of AP-1 to chromatin, resulting in the up-regulation of AP-1-dependent gene expression 20 . It can also bind to G/T-mismatch DNA and initiate the process of DNA mismatch repair 21 . FOXA1, another member of the forkhead transcription factors, has been shown to interact with ERa via its FOX domain, and mediates the recruitment of ERa to chromatin, leading to the upregulation of ERa target genes 22 . Other members of this protein family, such as FOXO3a can also interact with ERa via its FOX domain, but its action inhibits ERa transcriptional activities, causing a down-regulation in the expression of ERs target genes, and suppression of the proliferation of ERa-positive breast cancer cells 6 . Both FOXA1 and FOXO3a can interact with ERa via their FOX domains, but they exert completely different effects on the regulation of ERa. This suggests that FOX domain just mediates the interaction of forkhead proteins with ERa, whereas other domains in their structures may affect ERa function. FOXK2 contains a conserved FOX domain, and our preliminary data have shown that FOXK2 can inhibit the transcriptional activity of ERa. We therefore wanted to know whether FOXK2 can interact with ERa and regulate its function.
In this report, we observed a negative correlation between ERa and FOXK2 in human breast cancer. We demonstrated that FOXK2 could interact with ERa via the region containing FOX domain (amino acids 128 to 353), leading to lower protein stability for ERa, and inhibition of its transcriptional activity. Such regulation of ERa by FOXK2 occurred via a mechanism that involved BRCA1/ BARD1. We also showed that FOXK2 could suppress ERa-mediated proliferation of breast cancer cells. Taken together, our data suggested that FOXK2 might act as a negative regulator of ERa.
Results
FOXK2 is associated with ERa in human breast cancer. Aberrant ERa signaling is known to play an important role in the occurrence of ERa-positive breast cancer. However, little is known about the role of FOXK2 in tumorigenesis of breast cancer. In order to examine the relationship between FOXK2 and ERa in breast cancer, we compared the protein levels of FOXK2 and ERa in the breast cancer specimens (Fig. 1a) . A total of 53 breast tumor specimens (27 ERa-positive and 26 ERa-negative) were analyzed by immunohistochemical assay. According to the comparison of H-score, seventeen of the ERapositive samples (63%) showed low FOXK2 expression, whereas only eight of the ERa-negative samples (31%) showed low FOXK2 expression ( Fig. 1b ). We also examined the protein levels of endogenous ERa and FOXK2 in various breast cancer cell lines. As shown in Fig. 1c , the levels of FOXK2 expression in the ERa-positive breast cancer cell lines (MCF-7, T47D, ZR-51-30 and BT474) were significantly lower than that in ERa-negative breast cancer cell lines (MDA-MB-231 and Bcap-37). Taken together, these results suggested that a negative correlation existed between ERa and FOXK2 in breast cancer.
FOXK2 interacts with ERa in breast cancer cells. In breast cancer cells, FOXA1 and FOXO3a can regulate the function of ERa via their FOX domains, and since FOXK2 also contains a conserved FOX domain, we speculated that it too may interact with ERa. In order to investigate this possibility, we performed co-immunoprecipitation experiments in two different cell lines (MCF-7 and T47D) using either anti-FOXK2 or anti-ERa antibody. A positive interaction between endogenous FOXK2 and ERa was evident in MCF-7 and T47D cells (Figs. 2a and 2b). Similar co-precipitation of FOXK2 and ERa were obtained when the same immunoprecipitation experiment was carried out in HEK 293T cells that were transfected with EGFP-FOXK2 and Flag-ERa (Fig. 2c ). The interaction between FOXK2 and ERa was confirmed using mammalian two-hybrid system. Transactivation by pBIND-ERa was evident by co-expressing a pACT-FOXK2 fusion protein ( Fig. 2d ). Moreover, GST pull-down assay further confirmed the interaction between FOXK2 D1 and ERa in vitro ( Fig. 2e ). Double-label fluorescence immunohistochemistry carried out in MCF-7 cells showed that both of FOXK2 and ERa were localized in the nucleus (Fig. 2f FOXK2 decreases ERa protein level by promoting its ubiquitindependent degradation. Given that there was a negative correlation between ERa and FOXK2 in human breast cancer, we speculated that there may be a causal relationship between FOXK2 and ERa at the protein level. To investigate this possibility, MCF-7 cells were transfected with a control vector or His-Flag-FOXK2 and their endogenous levels of ERa were compared by Western blot. Overexpression of FOXK2 resulted in reduced ERa protein level ( Fig. 3a) . Considering that this could be also due to changes in level of ERa transcript, changes in ERa mRNA levels in MCF-7 cells were then examined. Real-time PCR analysis showed that overexpression of FOXK2 had no effect on the level of ERa mRNA (Fig. 3b ). Furthermore, knockdown of FOXK2 by siRNA pool (with four individual siRNAs targeting FOXK2 gene) increased the endogenous ERa protein level ( Fig. 3c ) without changing the level of ERa mRNA in MCF-7 cells ( Fig. 3d ), suggesting that the reduced level of ERa protein caused by FOXK2 was due to the change in ERa protein stability. Considering the stability of ERa is known to be regulated by proteasome-mediated degradation 23, 24 , the effect of overexpression of FOXK2 on the stability of ERa was further examined in the absence and presence of MG132, a proteasome inhibitor. In the absence of MG132, the protein level of endogenous ERa decreased with increasing dosages of FOXK2, whereas in the presence of MG132, the levels were similar among regardless of the dosages of FOXK2 ( Fig. 3e ), suggesting that MG132 could inhibit the proteasome-dependent degradation of ERa promoted by FOXK2. The half-life of ERa in MCF-7 cells transfected with or without wild-type FOXK2 was determined after the cells were treated with cycloheximide, an inhibitor of protein biosynthesis. The results demonstrated that overexpression of FOXK2 shortened the half-life of ERa from 11 h to 5 h ( Fig. 3f ) and increased the ubiquitination of ERa (Fig. 3g ). Taken together, these results suggested that FOXK2 could decrease the stability of ERa through promoting its ubiquitin-dependent degradation.
FOXK2 interacts with BARD1 and increases the ubiquitination of ERa. Protein sequence analysis showed that FOXK2 did not have the RING, U-box and HECT domains, which are catalytic domains of ubiquitin E3 ligase, and therefore FOXK2 may not function as an ubiquitin E3 ligase. So we speculated that FOXK2 may increase the ubiquitination of ERa through interaction with other E3 ligases. In order to examine which ubiquitin E3 ligase is involved in FOXK2promoted ubiquitination of ERa, we examined the interaction between FOXK2 and the ubiquitin E3 ligases of ERa. Coimmunoprecipitation experiments revealed a positive interaction between FOXK2 and BARD1 ( Fig. 4a ), whereas no interaction between FOXK2 and CHIP or FOXK2 and MDM2 was observed ( Fig. 4b and 4c ), suggesting that BRCA1/BARD1 might participate in FOXK2-mediated degradation of ERa. To further confirm the interaction of FOXK2 with BARD1, we performed co-immunoprecipitation experiment using MCF-7 cells and either anti-FOXK2 or anti-BARD1 antibody. A positive interaction between endogenous FOXK2 and BARD1 was observed ( Fig. 4d ). To map the region of FOXK2 that interacted with BARD1, we performed the same experiment for the different truncated FOXK2 mutants. Positive interaction was seen between BARD1 and FOXK2 FL or D1 or D2, whereas no interaction was detected between BARD1 and FOXK2 D3 or D4 ( Fig. 4e ), suggesting that the interaction of FOXK2 and BARD1 was mediated by the amino-terminal region containing FHA domain (amino acids 1 to 128) of FOXK2. Double-label fluorescence immunohistochemistry further revealed that both FOXK2 and BARD1 were localized in the nucleus of the cell (Fig. 4f ). Given that FOXK2 could interact with both ERa and BARD1, we speculated that an ERa-FOXK2-BARD1 complex might exist. To investigate this possibility, we performed re-immunoprecipitation and Western blot assay. A band was detected when extract of His-Flag-FOXK2 were subjected to immunoprecipitation with anti-Flag antibody followed by Western blot with anti-HA antibody or vice versa. (b) HEK 293T cells transfected with appropriate plasmids were subjected to immunoprecipitation and Western blot with specific antibodies as indicated or vice versa. (c) MCF-7 cells were subjected to immunoprecipitation with anti-MDM2 antibody followed by Western blot with anti-FOXK2 antibody or vice versa. (d) MCF-7 cells were subjected to immunoprecipitation with anti-BARD1 antibody followed by Western blot with anti-FOXK2 antibody or vice versa. (e) HEK 293T cells transfected with HA-BARD1 and different FOXK2 constructs as indicated were collected and then subjected to immunoprecipitation with anti-HA antibody, followed by Western blot analysis with anti-Flag antibody. (f) MCF-7 cells transfected with EGFP-FOXK2 and HA-BARD1 were stained with rabbit anti-HA antibody and TRITC-conjugated anti-rabbit IgG, and then counterstained with DAPI (blue) for nucleus detection. EGFP-FOXK2 appeared as green signal when visualized by fluorescence microscopy. (g) MCF-7 cells transfected with Flag-ERa and HA-BARD1 were subjected to immunoprecipitation with anti-Flag antibody and re-immunoprecipitation (RE) with anti-HA antibody followed by Western blot with anti-FOXK2 antibody, anti-Flag or anti-HA antibody. (h) HEK 293T cells transfected with appropriate plasmids as indicated, and then treated with 10 mM MG132 for 8 h. Cells were collected and then subjected to immunoprecipitation with anti-Flag antibody followed by Western blot with the indicated antibodies. (i) HEK 293T cells transfected with appropriate plasmids as indicated, and then treated with 10 mM MG132 for 8 h. Cells were collected and then subjected to immunoprecipitation with anti-Flag antibody followed by Western blot with the indicated antibodies. (j) HEK 293T cells transfected with various combinations of different constructs as indicated were treated with 10 mM MG132 for 8 h. The cells were collected and subjected to immunoprecipitation with anti-ERa antibody followed by Western blot analysis with anti-Myc antibody. All experiments were repeated at least three times. The full-length blot of Figure 4 is presented in Supplementary Figure 4. www.nature.com/scientificreports SCIENTIFIC REPORTS | 5 : 8796 | DOI: 10.1038/srep08796 MCF-7 cells that overexpressed Flag-ERa and HA-BARD1 was probed with anti-FOXK2 antibody (Fig. 4g ), indicating the existence of ERa-FOXK2-BARD1 complex. We further examined whether FOXK2 could affect the interaction of ERa with BARD1. The results showed that overexpression of FOXK2 enhanced the interaction between ERa and BARD1 (Fig. 4h ), whereas knockdown of FOXK2 by siRNA decreased this interaction (Fig. 4i) , indicating that FOXK2 probably acted as a scaffold protein to enhance the interaction of BRCA1/BARD1 with ERa. Next, we examined the effect of FOXK2 on BARD1-mediated ubiquitination of ERa. As shown in Fig. 4j , both FOXK2 and BARD1 enhanced the ubiquitination of ERa, with the extent of ubiquitination being enhanced when both FOXK2 and BARD1 were overexpressed. In contrast, knockdown of FOXK2 decreased the ubiquitination of ERa. Taken together, these results suggested that FOXK2 probably facilitated the interaction of ERa with its ubiquitin E3 ligase BRCA1/ BARD1 complex, therefore, promoting the ubiquitin-mediated degradation of ERa.
FOXK2 suppresses the transcriptional activity of ERa. FOXK2promoted degradation of ERa was expected to have a negative effect on the transcriptional activity of ERa. Therefore, the effect of FOXK2 on the transcriptional activity of ERa was determined by using a reporter gene construct consisting of estrogen responsive elementluciferase (ERE-luc). MCF-7 and T47D cells were transfected with the ERE-luc construct and ERa only, or ERE-luc, ERa and FOXK2, and the level of reporter activity in these cells was measured following treatment with or without 17b-estradiol (E2). As shown in Fig. 5a , in the presence of E2 treatment, ERE-luc activity was highest when the cells overexpressed ERa alone. However, when these cells also overexpressed FOXK2, the level of ERE-luc activity was significantly reduced in a dose-dependent manner. Indeed, FOXK2 could both inhibit the transcriptional activity of ERa in the absence and presence of E2 treatment. These results corresponded to the reduction of ERa protein detected by Western blot (Fig. 3e) . Cyclin D1 is a classical ERa-targeted gene and its promoter contains EREs. Similar results were obtained when the same experiment was carried out using MCF-7 and T47D cells that were transfected with Cyclin D1-luc, Flag-ERa and His-Flag-FOXK2 with or without E2 treatment (Fig. 5b ). Next, we detected the effect of different FOXK2 constructs on the transcriptional activity of ERa using MCF-7 and T47D cells. Luciferase reporter assay showed that the transcriptional activity of ERa in cells transfected with FOXK2 FL significantly decreased compared to non-transfected cells; the transcriptional activity of ERa in cells transfected with FOXK2 D1 was similar to that in cells transfected with FOXK2 FL, whereas the transcriptional activity of ERa in cells transfected with FOXK2 D2 and D3 increased significantly, compared with that in cells transfected with FOXK2 D1 both in the cases of MCF-7 and T47D cells ( Fig. 5c and 5d ). Furthermore, we examined the ability of FOXK2 to regulate the expression of the well-established ERatargeted genes (Cyclin D1 and GREB1) in MCF-7 cells. Real-time PCR analysis showed that overexpression of FOXK2 reduced the mRNA levels of both Cyclin D1 and GREB1 (Fig. 5e ). Taken together, these results showed that FOXK2 might suppress the transcriptional activity of ERa through promoting its degradation, and in doing so, it caused the down-regulation of the expression of ERa target genes.
FOXK2 suppresses ERa-mediated growth of breast cancer cell. As FOXK2 was able to interact with ERa, and regulate its function, it may in fact affect ERa-mediated proliferation of breast cancer cells, especially since ERa is known to play a major role in the proliferation of breast cancer. Crystal violet staining assay showed that MCF-7 cells transfected with Flag-ERa produced more colonies than cells that were transfected with an empty vector (control cells) or cells that were transfected with both Flag-ERa and His-Flag-FOXK2 (Fig. 6a) . In contrast, knockdown of ERa decreased, whereas knockdown of FOXK2 increased the colony numbers of MCF-7 cells compared with the control groups, whereas knockdown of FOXK2 increased the colony numbers of MCF-7 cells compared with control group. However when ERa was also knocked down, knockdown of FOXK2 had no effect on cell proliferation (Fig. 6b ). We also examined the effect of FOXK2 on cell viability. Growth of both MCF-7 and T47D cells was inhibited when these cells were transfected with FOXK2 and cultured either in the absence of presence of E2 (Fig. 6c ). The effect of FOXK2 on the cell-cycle was also investigated. MCF-7 cells transfected with either Flag-ERa or His-Flag-FOXK2 or both were subjected to flow cytometry analysis to evaluate the cell cycle profile of asynchronous cells. Cells transfected with ERa showed an overall increase in the percentage of cells in the S phase, with a corresponding reduction in the percentage of cells in G0/G1 phase compared with control cells (Fig. 6d) . In contrast, the percentage of cells in the S phase decreased for cells transfected with FOXK2 decreased the percentage of S phase cells compared with control cells. When the cells were transfected with both ERa and FOXK2, the percentage of S phase cells decreased compared with cells only transfected with ERa. Taken together, these results suggested that FOXK2 could suppress the growth of breast cancer cells through its modulation of ERa.
Discussion
Growing evidence has shown that ERa plays a key role in the initiation and development of breast cancer, and this has made ERa a valuable predictive and prognostic biomarker for the treatment of breast cancer [25] [26] [27] . However, much of the detailed mechanism involved in the regulation of ERa function is still unclear, and this appears to restrict our understanding of the pathogenesis of ERapositive breast cancer. Thus it is important to gain further insight into how ERa function is regulated. In this study, we focused on the role of FOXK2 in ERa-positive breast cancer cells as this would allow us to investigate the connection between FOXK2 and ERa in breast cancer and to interpret this connection in terms of its significance in biological function.
The forkhead transcription factors are an evolutionarily conserved family of proteins. In mammals, there are over 40 different forkhead transcription factors, and these proteins control several cellular processes, including growth, development, proliferation and cell cycle through regulating the expression of their target genes [28] [29] [30] . Forkhead transcription factors also interact with other transcription factors, and regulate their functions, such as the co-association of FOXA1 with ER and AR 22, 31 , FOXO3a with ERa and ERb 7 , FOXM1 with Sp1 32 and p53 33 , and FOXO1A with HoxA-11 34 . The data from breast tumor specimens that we analyzed indicated a negative correlation between FOXK2 and ERa (Fig. 1) . Furthermore, the data from coimmunoprecipitation, mammalian two hybrid system and GST pulldown assay clearly revealed that FOXK2 interacted with ERa ( Figs. 2a-e ), although we could not conclude from our data whether FOXK2 and ERa directly interact with each other or via some an accessory element. The interaction was obvious and real, and subsequent reporter gene assay showed that FOXK2 suppressed the transcriptional activity of ERa and it achieved this through affecting its protein stability rather than its gene expression ( Figs. 5a-d) . The mechanism may stem from FOXK2 playing a structural role, such as stabilizing the protein complex, thereby making ERa more readily for ubiquitination. In the case of FOXO3a, its interaction with ERa has been demonstrated to occur via its FOX domain, and this interaction also results in the inhibition of ERa transcriptional activity 7 . However, whether FOXO3a affects ERa at the level of protein or gene was not demonstrated. We not only identified the exact domain of FOXK2 that interacted with ERa, but also showed that such interaction led to enhanced the degradation of ERa via the proteasome, and hence, its loss of transcriptional activity.
Ubiquitin-dependent protein degradation plays an important role in many basic cellular functions through regulating different cell regulators, such as tumor regulators, transcriptional factors and cell surface receptors 35, 36 . Before the target protein is degradated by 26S proteasome, it must be attached conjugated to ubiquitin, a process that is catalyzed by an E3 ubiquitin ligase [37] [38] [39] [40] . FOXK2 lacks the catalytic domains of ubiquitin E3 ligase, and does not have the function of ubiquitin E3 ligase. Thus we speculated that FOXK2 may increase the ubiquitination of ERa through regulating the interaction between ERa and its E3 ligases. Indeed, FOXK2 interacted with BARD1 and thus, the BRCA1/BARD1 complex could be responsible for the degradation of ERa. If so, then FOXK2 would appear to mediate the degradation of ERa via an accessory protein, BARD1. Furthermore, FOXK2 interacted with ERa and BARD1 at different domains ( Figs. 2e and 4d ), suggesting that the interaction was rather specific in each case. The involvement of BARD1 in FOXK2-regulated ERa activity was clearly supported by the data which showed that overexpression of FOXK2 promoted the interaction between BARD1 and ERa (Fig. 4h ), whereas knockdown of FOXK2 weakened their interaction (Fig. 4i) .
ERa is a member of the steroid hormone receptor superfamily of ligand-activated transcription factors. As a transcription factor, ERa plays a crucial role in regulating the normal function of reproductive tissues and proliferation of epithelial cells. It also plays an important role in the genesis and malignant progression of breast cancer. Aberrant activation of ERa contributes to tumorigenesis of the breast by up-regulating its target genes such as TFF1, SDF-1, Cyclin D1 and GREB1 41-45 . Among them, Cyclin D1 is a major regulator that governs the entrance of a cell into the proliferative stage of the cell cycle, www.nature.com/scientificreports SCIENTIFIC REPORTS | 5 : 8796 | DOI: 10.1038/srep08796 and its expression is regulated by ERa, which mediates its proliferative action on mammary cancer cells 44 . Thus, there is a strong correlation between increased proliferative response and increased levels of Cyclin D1 mRNA, and this could be seen from the increased levels of ERa in MCF-7 cells that stably expressed ERa compared to control cells (no overexpression of ERa 46 . Our data here that the mRNA level of Cyclin D1 was up-regulated in MCF-7 cells following treatment with E2, whereas this up-regulation was inhibited when the cells overexpressed FOXK2. The upregulation of GREB1 mRNA level was also inhibited by FOXK2 (Fig. 5e) , and was consistent with the result obtained for Cycline D1. This indicated that FOXK2 could suppress the transcriptional activity of ERa, which would effectively down-regulate the expression of genes that are regulated by ERa.
Since FOXK2 could act as a negative regulator of ERa, we expected it to play a role in ERa-mediated cell proliferation. According to our data, either overexpression of ERa alone or knockdown of FOXK2 in MCF-7 cells could result in significant increases in cell number compared to control cells (no overexpression or knockdown of exogenous ERa or FOXK2) ( Fig. 6a and 6b ). This clearly showed that increase in the level of ERa activity resulting either from increased expression of the gene from exogenous source or from crippling FOXK2 (which had the effect of amplifying ERa activity) would ultimately lead to increased cell growth. A similar trend was observed in the cell viability assay (Fig. 6c ). Furthermore, FOXK2 appeared to suppress ERa-mediated proliferation of breast cancer cells through inhibiting cell cycle progression (Fig. 6d) .
In conclusion, we showed in this study that FOXK2 negatively regulated the function of ERa through enhancing its degradation via the proteasome, and identified the ubiquitin E3 ligase BRCA1/ BARD1 complex as an important contributing factor. This negative regulation of ERa by FOXK2 would disrupt the ERa-mediated cell growth, and in the case of breast cancer cells, it would mean a reduction in cell proliferation and possibly, the spread of cancer cells. However, since ERa is also needed for the normal functioning of the cell, targeting it with a negative regulator gene that would result in its degradation is not an ideal strategy for combating breast cancer, even for ERa-positive breast cancer. Therefore, further work is desirable, such as more in depth investigation of the molecular interaction between FOXK2 and ERa and their effect on normal cells.
Methods
Ethics statement. The study involving human participants was approved by the institutional review board of Dalian University of Technology. Written consent was obtained from all the participants. The methods were carried out in accordance with the approved guidelines. All clinical research was performed on the basis of the principles expressed in the Declaration of Helsinki.
Plasmids and antibodies. His-Flag-tagged FOXK2 and EGFP-FOXK2 were gifts kindly provided by Dr. Andrew D. Sharrocks (University of Manchester). HA-BARD1 was a gift kindly provided by Tomohiko Ohta (St. Marianna University). Cyclin D1-luc was kindly provided by Dr. Robert Weinberg (Whitehead Institute for Biomedical Research). Flag-tagged full-length and truncated FOXK2 (D1, D2, D3 and D4) were constructed according to standard PCR-based cloning procedures using His-Flag-FOXK2 as templates. PCR fragments were inserted into pcDNA3.1-33Flag at the BamHI and HindIII sites. Plasmid encoding GST-fusion protein was prepared by standard PCR methods using His-Flag-FOXK2 as templates, and the PCR fragment was cloned in frame into pGEX-4T3 (Amersham Pharmacia) at the BamHI and SalI sites. SMARTpoolH siRNAs (Control, ERa and FOXK2) with four individual siRNAs targeting a single gene were obtained from Thermo (USA).
Rabbit polyclonal anti-Flag, anti-HA, anti-ERa, anti-GFP, anti-IgG and mouse monoclonal anti-Actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-ERa and anti-GST antibodies were obtained from Millipore. Mouse monoclonal anti-HA and anti-GFP antibodies were obtained from GeneTex. Rabbit polyclonal anti-c-Myc and mouse monoclonal anti-Flag (M2) antibodies were purchased from Sigma. Goat polyclonal anti-FOXK2 (ILF1, ab5298) and rabbit polyclonal anti-FOXK2 (ILF1, ab84761) antibodies were obtained from Abcam. Rabbit polyclonal anti-BARD1 antibody was obtained from BIOSS (Beijing, China). Rabbit polyclonal anti-MDM2 antibodies were obtained from Sangon (Shanghai, China). Cycloheximide was obtained from Sigma, and MG132 was obtained from Merck.
Cell culture and transfection. HEK 293T, MCF-7, Bcap-37, MDA-MB-231 and T47D cells had been used in our previous study 47, 48 . ZR-51-30 and BT474 cells were obtained from the cell bank of the Shanghai branch of Chinese Academy of Sciences. Unless other stated, all cell cultures were incubated at 37uC in the presence of 5% CO 2 . HEK 293T, MCF-7, Bcap-37, MDA-MB-231 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 10% fetal bovine serum (Hyclone) and penicillin-streptomycin (100 U/ml penicillin and 0.1 mg/ml streptomycin). ZR-51-30 and BT474 cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum, penicillin-streptomycin. T47D cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum, penicillin-streptomycin and insulin (5 g/ml). For E2 stimulation experiments, MCF-7 and T47D cells were subjected to serum starvation for 24 h in 2% charcoal-stripped fetal bovine serum (Gibico) and phenol red free medium, and then treated with or without 10 nM E2 for 16 h. Lipofectamine 2000 (Invitrogen) was used for cell transfection. Corresponding empty vectors were used in each transfection experiment to guarantee the same amount of plasmids for all parallel groups. All transfection experiments were transient transfection.
Immunoprecipitation and Western blot. Cells were harvested and then lysed in a cold hypotonic buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate and a mixture of protease inhibitors. After centrifugation at 10000 3 g/4uC for 10 min, the supernatant was incubated with the desired antibody or with control IgG and protein A-Sepharose (Amersham Biosciences) or protein G-Sepharose (Santa Cruz, CA) at 4uC for overnight. After that, the sample was centrifuged at 5000 3 g/4uC for 10 min and the pellet was washed twice with Washing Buffer I (50 mM Tris-HCl [pH 7.5], 150 mM sodium chloride, 1% NP-40 and 0.05% sodium deoxycholate) and once with Washing Buffer II (50 mM Tris-HCl [pH 7.5], 500 mM sodium chloride, 0.1% NP-40, and 0.05% sodium deoxycholate), and then subjected to SDS-PAGE. After electrophoresis, protein bands in the gel were transferred to PVDF membrane (Millipore), and probed with the specified primary antibody, followed by the appropriate secondary antibody, and then visualized using the enhanced chemiluminescence detection reagents (Thermo). Immunoblot data were quantified by scanning the appropriate bands of interest and plotted as relative density of gray scale. Re-immunoprecipitation was conducted as previously described 49 .
Immunofluorescence staining. MCF-7 cells were cultured for overnight on cover slips. After 24 h, the cells were fixed in 1% paraformaldehyde for 15 min at room temperature, permeabilized with methanol for 40 min at 220uC and then blocked with 0.8% BSA for 1 h at 4uC. The cells were then incubated with appropriate antibodies at 4uC for overnight, followed by further incubation with TRITCconjugated anti-rabbit IgG for 1 h. The cover slips were then mounted on glass slides with mounting medium containing 49, 6-diamidino-2-phenylindole (DAPI). Images were taken with a confocal fluorescence microscope (Olympus FV1000-IX81, Tokyo, Japan).
Immunohistochemical assay. A total of 53 breast cancer specimens were obtained from female patients of Han Chinese descent, with a median age of 59.1 years, ranging from 39 to 78 years. Out of 53 specimens, 27 were ERa-positive, and 26 were ERanegative as determined by clinical diagnosis performed by Qiqihar Medical University. Sections (4 micrometers thickness) of the obtained specimens were cut out and used for immunohistochemical analysis. The immunohistochemical assay kit was obtained from Maixin Bio. Immunohistochemical assay was conducted as previously described 50 . The primary antibodies used in immunohistochemical assay were rabbit anti-human FOXK2 and mouse anti-human ERa. The levels of FOXK2 and ERa expression were quantified according to their H-scores 51 . ERa was considered positive if the H-score was more than 1 52, 53 . The median H-score of all samples was used as a cutoff for grouping the samples into high or low FOXK2 expression category 54 .
Luciferase reporter assay. Cells were cultured in a 24-well plate for 24 h. The cells were then transfected with the appropriate plasmid construct using Lipofectamine 2000 (Invitrogen). Eighteen hours after transfection, the medium was replaced with phenol red-free medium containing 2% charcoal-stripped fetal bovine serum for 24 h, followed by treatment with or without 10 nM E2 for 16 h. The cells were harvested and Luc reporter assay was performed in accordance to the manufacturer's instructions (Promega, Madison, WI, USA).
Mammalian two hybrid assay. The checkmate TM mammalian two-hybrid system was obtained from Promega. ERa and FOXK2 were subcloned into BamHI-SalI cut pACT and pBIND, respectively.
GST pull-down assay. The GST alone and GST fusion protein were expressed in E. coli BL21 (Takara), and purified by Pierce GST Spin Purification Kit (Thermo scientific). GST pull-down assay was performed using a Pierce GST Protein Interaction Pull-Down Kit (Thermo scientific). The purified GST-tagged fusion protein (BAIT) was immobilized on the Pierce Spin Column. MCF-7 cells were lysed in pull-down lysis buffer containing DNase (Takara). The supernatant was loaded onto the Pierce Spin Column, and then incubated at 4uC for 2 hour with gentle agitation. The column was centrifuged at 1250 3 g for 1 minute and the flow through was discarded. Then the column was washed five times using wash solution. Elution buffer was added to the column followed by 5-min incubation with gentle agitation. After that, the column was centrifuged at 1250 3 g for 1 minute, and the eluent was subjected to Western blot assay.
Cell growth assays. MTT and Flow Cytometry assays were performed as previously described 47, 54 . For Flow Cytometry assay, MCF-7 cells transfected with different plasmids were stained with propidium iodide (PI) (BD Pharmingen, CA). Experimental data were collected by FACSCalibur (BD Biosciences, San Jose, CA, USA). Cell cycle profiles were determined using ModFit LT (BD Biosciences). For crystal violet staining assay, MCF-7 cells transfected with the appropriate plasmids were transferred to 35 mm plate, and were cultured until the recognizable clones appeared. Then, the cells were stained with crystal violet for 30 min at room temperature.
www.nature.com/scientificreports
Real-time PCR. MCF-7 cells were transfected with appropriate plasmids. Twenty four hours after transfection, the cells were replaced with phenol red-free medium containing 2% charcoal-stripped fetal bovine serum for 24 h, then treated with or without 10 nM E2 for 16 h. Total RNA was isolated from the cells using TRIzol reagent (Takara), and then subjected to reverse transcription with oligo(dT)15. The mRNA levels of ERa, Cyclin D1, GREB1 and GADPH (as an internal control) were quantitated by real-time PCR using Corbett Research RG 3000 analyzer (Australia), Maxima SYBR Green/ROX qPCR (Thermo Scientific). The following primer sequences were used: ERa: 59-ACTCGCTACTGTGCAGTGTGCAAT (forward) and 59-CCTCTTCGGTCTTTTCGTATCCCA (reverse); Cyclin D1: 59-GCTGCTCCTGGTGAACAAGC (forward) and 59-AAGTGTTCAATGAAATCGTGCG (reverse); GREB1: 59-CAGGCTTTTGCACCGAATCT (forward) and 59-CAAAGCGTGTCGTCTTCAGCT (reverse); GADPH: 59-GGGTTGAACCATGAGAAGT (forward) and 59-GACTGTGGTCATGAGTCCT (reverse). The mRNA levels of ERa, Cyclin D1 and GREB1 were normalized against GAPDH, which served as an endogenous control. Each gene was measured in triplicate.
Statistical analysis. A Chi-square (x 2 ) test was used to examine the correlation between FOXK2 and ERa gene expression in breast cancer tissues from 53 patients. All statistical analyses of other data were performed with ANOVA, followed by the Bonferroni test for pairwise comparisons 55, 56 . Data were given as means 6 SDs, and significance was considered at the P value , 0.05 level.
